Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation (By similarity).. Additionally we are shipping Lrig1 Proteins (10) and Lrig1 Kits (2) and many more products for this protein.
Showing 10 out of 61 products:
Mouse (Murine) Polyclonal Lrig1 Primary Antibody for FACS, ICC - ABIN4900308
Jensen, Driskell, Watt: Assaying proliferation and differentiation capacity of stem cells using disaggregated adult mouse epidermis. in Nature protocols 2010
Show all 9 references for ABIN4900308
Human Polyclonal Lrig1 Primary Antibody for IL, WB - ABIN3197485
Ledda, Bieraugel, Fard, Vilar, Paratcha: Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2008
Show all 6 references for ABIN3197485
Mouse (Murine) Polyclonal Lrig1 Primary Antibody for WB - ABIN1881506
Ye, Gao, Xu, Zeng, Ou, Mao, Wang, He, Wang, Yang, Guo, Lei: Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. in Journal of neuro-oncology 2009
Show all 2 references for ABIN1881506
Mouse (Murine) Polyclonal Lrig1 Primary Antibody for FACS - ABIN4897517
Wong, Stange, Page, Buczacki, Wabik, Itami, van de Wetering, Poulsom, Wright, Trotter, Watt, Winton, Clevers, Jensen: Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. in Nature cell biology 2012
Human Polyclonal Lrig1 Primary Antibody for FACS, IHC - ABIN4900286
Oh, Lee, Choi, Suh, Shim, Song, Kim, Lee, Oh, Jeong, Cheong, Song, Kim: USP8 modulates ubiquitination of LRIG1 for Met degradation. in Scientific reports 2014
LRIG1 and Fascin-1 (show FSCN1 Antibodies) were differently expressed in cancer and normal lung tissue in patients with NSCLC, which could be a biomarker for mediastinal lymph node metastasis in NSCLC patients.
Results suggest that the LRIG1could negatively control MRP-1 (show MDM4 Antibodies) and the apoptosis to improve the sensitivity of VP16-related chemotherapy.
ERa-dependent expression of LRIG1 dampens ErbB3 (show ERBB3 Antibodies) signaling in luminal breast cancer cells, and by blocking ERa activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 (show ERBB3 Antibodies) accumulation, enhanced ErbB3 (show ERBB3 Antibodies) signaling to cell survival pathways
These findings demonstrate that LRIG1 is an independent prognostic factor in patients with non-small cell lung cancer
LRIG1 expression was associated with pathological type, differentiation status, and stage of Non-small Cell Lung Cancer. The result showed that LRIG1 was an independent prognostic factor for OS of NSCLC patients.
The inhibitory effects of LRIG1 are most likely mediated by suppression of the EGFR (show EGFR Antibodies)/PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) pathway and epithelial-mesenchymal transition (EMT (show ITK Antibodies)) process.
LRIG1 can enhance chemosensitivity in glioblastoma by inhibition of BCL-2 (show BCL2 Antibodies) and MnSOD (show SOD2 Antibodies)
Results showed that leucine-rich repeats and immunoglobulin-like domains can reverse multidrug resistance in glioblastoma, by negatively regulating epidermal growth factor receptor (show EGFR Antibodies).
MiR (show MLXIP Antibodies)-20a mediated temozolomide-resistance in glioblastoma cells through negatively regulating LRIG1 expression.
Based on these results, we concluded that the upregulation of LRIG1 expression inhibited the EGFR (show EGFR Antibodies) signaling pathway, activated the mitochondrial pathway of apoptosis and eventually increased the sensitivity of bladder cancer cells to CDDP.
LRIG1+ cells were found to re-populate the neo-epidermis on day 14, suggesting an important homeostatic role of LRIG1 in skin
a subset of human duodenal tumors exhibited features of LRIG1(-/-) adenomas, including loss of LRIG1, gastric metaplasia (MUCIN5AC and MUCIN6), and increased amphiregulin (show AREG Antibodies) and Egfr (show EGFR Antibodies) activity.
LRIG1 regulates the postnatal development of ICC-DMP and ICC-SMP from smooth muscle progenitors in mice.
Loss of one Apc (show APC Antibodies) allele in Lrig1(+) cells results in inducible stem cell-driven model that recapitulates features of familial adenomatous polyposis.
At later stages, Lrig1 expression is sustained in non-sensory tissues, whereas Lrig2 levels are enhanced in neurons and sensory epithelia.
LRIG1 orchestrates corneal-tissue transparency and cell fate during repair via STAT3 (show STAT3 Antibodies).
A review summarizes the data that LRIG1 is a ERBB (show EGFR Antibodies) negative regulator and tumour suppressor.
LRIG1 Loss of heterozygosity (LOH) is frequent across cancers and its loss is an early event in the development of human squamous carcinomas.
The Lrig1, a negative-feedback regulator of the ErbB (show EGFR Antibodies) receptor family, is highly expressed by intestinal stem cells and controls the size of the intestinal stem-cell niche by regulating the amplitude of growth-factor signalling.
Study demonstrates that Lrig1 null mice develop duodenal adenomas, providing in vivo evidence that the ErbB (show EGFR Antibodies) negative regulator Lrig1 functions as a tumor suppressor.
Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation (By similarity).
leucine-rich repeat protein LRIG1
, leucine-rich repeats and immunoglobulin-like domains protein 1
, ortholog of mouse integral membrane glycoprotein LIG-1
, integral membrane glycoprotein